Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
IGM Biosciences, Inc.
Taiho Pharmaceutical Co., Ltd.
TG Therapeutics, Inc.
Eli Lilly and Company
Valerio Therapeutics